published meta-analysis   sensitivity analysis   studies

IFN beta-1a in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsDavoudi-Monfared, 2020 0.30 [0.11; 0.83] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] 0.70[0.13; 3.86]Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021279%1,050seriousnot evaluable deathsdetailed resultsDavoudi-Monfared, 2020 0.38 [0.16; 0.87] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] 0.76[0.17; 3.38]Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021275%1,061seriousnot evaluable deaths (time to event analysis only)detailed resultsDavoudi-Monfared, 2020 0.38 [0.16; 0.87] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] 0.76[0.17; 3.38]Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021275%1,061seriousnot evaluable clinical improvementdetailed resultsDavoudi-Monfared, 2020 1.10 [0.64; 1.88] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] 1.00[0.88; 1.13]Davoudi-Monfared, 2020, Kalil (ACTT-3), 202120%1,050moderatenot evaluable clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] 1.01[0.79; 1.29]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvement (time to event analysis only)detailed resultsDavoudi-Monfared, 2020 1.10 [0.64; 1.88] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] 1.00[0.88; 1.13]Davoudi-Monfared, 2020, Kalil (ACTT-3), 202120%1,050moderatenot evaluable hospital dischargedetailed resultsDavoudi-Monfared, 2020 1.96 [0.76; 5.03] 1.96[0.76; 5.03]Davoudi-Monfared, 202010%81NAnot evaluable mechanical ventilationdetailed resultsDavoudi-Monfared, 2020 0.72 [0.29; 1.76] 0.72[0.29; 1.76]Davoudi-Monfared, 202010%81NAnot evaluable off oxygenationdetailed resultsDavoudi-Monfared, 2020 8.57 [1.43; 51.36] 8.57[1.43; 51.36]Davoudi-Monfared, 202010%32NAnot evaluable superinfectiondetailed resultsDavoudi-Monfared, 2020 2.41 [0.75; 7.73] 2.41[0.75; 7.73]Davoudi-Monfared, 202010%81NAnot evaluable0.520.01.0relative treatment effectwww.metaEvidence.org2024-04-28 11:44 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 881,904 - roots T: 290